FindTrial
Sign In

Pretreatment multi-phase enhanced CT image analysis to predict the response of inoperable gastric cancer to chemotherapy and immunotherapy

Multiphase contrast-enhanced CT imaging for predicting response to chemotherapy combined with immunotherapy in unresectable gastric cancer

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500111915
Enrollment
Unknown
Registered
2025-11-07
Start date
2025-11-07
Completion date
Unknown
Last updated
2025-11-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric carcinoma

Interventions

response and no response:None

Sponsors

The first affiliated hostipal of nanchang university
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1.Histologically confirmed gastric adenocarcinoma; 2.Receiving at least 2 cycles of immunotherapy; 3.Available data from baseline enhanced abdominal CT scan performed 30 days prior to immunotherapy; 4.The cancer has at least one evaluable lesion that meets the Efficacy Evaluation Criteria in Solid Tumors (RECIST 1.1). 5.CT imaging data complete before and after anti-PD-1 treatment;

Exclusion criteria

Exclusion criteria: 1.Lesions that cannot be clearly displayed on CT images or metastatic lesions that cannot be measured or assessed; 2.Presence of other primary tumors; 3.gastric stump carcinoma;

Design outcomes

Primary

MeasureTime frame
Complete response;Partial response;Stable disease;Disease progression;—

Countries

China

Contacts

Public ContactJiang Gunguang

The first affiliated hostipal of nanchang university

fbron.student@sina.com+86 791 86319551

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026